logo
Securities Fraud Investigation Into Biohaven Ltd. (BHVN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Securities Fraud Investigation Into Biohaven Ltd. (BHVN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Business Wire18-07-2025
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Biohaven Ltd. ('Biohaven' or the 'Company') (NYSE: BHVN) investors concerning the Company's possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON BIOHAVEN LTD. (BHVN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On July 17, 2023, Biohaven disclosed that the FDA had rejected the New Drug Application ('NDA') for its spinocerebellar ataxia ('SCA') treatment, troriluzole, having refused to even review the application after the Phase 3 SCA Trial had failed to meet its primary endpoint. On this news, Biohaven's stock price fell $5.38, or 22.6%, to close at $18.42 per share on July 27, 2023, thereby injuring investors.
Then, on March 3, 2025, Biohaven released its fourth quarter and full year 2024 financial results, disclosing that recent data from a late-stage study of its BHV-7000 treatment for bipolar mania 'did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure[.]' On this news, Biohaven's stock price fell $5.12, or 13.8%, to close at $32.06 per share on March 3, 2025.
Then, on April 25, 2025, news reports emerged that, according to the European Medicines Agency ('EMA'), Biohaven had withdrawn its Marketing Authorization Application ('MAA') for troriluzole in late March 2025. On this news, Biohaven's stock price fell $3.56, or 15.2%, to close at $19.84 per share on April 25, 2025.
Then, on May 14, 2025, Biohaven announced that 'the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the [Prescription Drug User Fee Act ('PDUFA')] date for the troriluzole [NDA] for the treatment of [SCA] by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA,' and that '[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.' On this news, Biohaven's stock price fell $3.84, or 19.5%, to close at $15.82 per share on May 15, 2025, thereby injuring investors further.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding Biohaven should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.
About Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.
With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

C3 AI (AI) Loses 10.8% as CEO Steps Down
C3 AI (AI) Loses 10.8% as CEO Steps Down

Yahoo

timean hour ago

  • Yahoo

C3 AI (AI) Loses 10.8% as CEO Steps Down

We recently published . Inc. (NYSE:AI) is one of the worst-performing stocks on Thursday. C3 AI snapped a two-day rally on Thursday, losing 10.84 percent to close at $26 apiece as investors repositioned portfolios following its chief executive's announcement that he was stepping down from his post. In a statement, Inc. (NYSE:AI) said that CEO Thomas Siebel has tendered his resignation due to health reasons, effective upon a successor assuming his post. 'After being diagnosed with an autoimmune disease in early 2025, I have experienced significant visual impairment,' he said. 'For C3 AI to reach its full potential—which I believe is spectacular—the board and I have initiated a search for a new CEO who can take the company to the next level of growth and success. I will remain fully engaged as Chief Executive Officer of until such time as the board appoints my successor, after which I will continue in the role of Executive Chairman, focusing on strategy, product innovation, strategic partner and customer relationships,' he noted. Meanwhile, an analyst from Wedbush said that the chief's resignation presented an opportunity for other firms to acquire Inc. (NYSE:AI). Wedbush gave Inc. (NYSE:AI) an 'outperform' rating and a price target of $35 apiece. While we acknowledge the potential of AI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .

Chipotle Mexican Grill (CMG) Slashes 13% on Disappointing Q2, Outlook
Chipotle Mexican Grill (CMG) Slashes 13% on Disappointing Q2, Outlook

Yahoo

timean hour ago

  • Yahoo

Chipotle Mexican Grill (CMG) Slashes 13% on Disappointing Q2, Outlook

We recently published . Chipotle Mexican Grill, Inc. (NYSE:CMG) is one of the worst-performing stocks on Thursday. Chipotle Mexican Grill fell by 13.34 percent on Thursday to close at $45.74 apiece as investors digested a mixed earnings performance and weak outlook for the rest of the year. In its earnings release, Chipotle Mexican Grill, Inc. (NYSE:CMG) said net income for the second quarter of the year dropped by 4.3 percent to $436 million from $455.7 million in the same period last year. Total revenues, on the other hand, grew by 3 percent to $3.06 billion from $2.97 billion year-on-year, driven by new restaurant openings. Comparable store sales, however, decreased by 4 percent due to lower transactions. Looking ahead, the company expects same-store sales to remain flat year-on-year, but it is working on initiatives to boost performance, including improving execution, introducing new menu innovations, amplifying the rewards program, and expanding globally.3 Pixabay/Public domain Additionally, Chipotle Mexican Grill, Inc. (NYSE:CMG) also expects between 25 and 27 percent of tax rate before discrete items for the full year. While we acknowledge the potential of CMG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Sign in to access your portfolio

Ardagh Metal (AMBP) Drops 16% as Traders Shun Q2 Earnings
Ardagh Metal (AMBP) Drops 16% as Traders Shun Q2 Earnings

Yahoo

timean hour ago

  • Yahoo

Ardagh Metal (AMBP) Drops 16% as Traders Shun Q2 Earnings

We recently published . Ardagh Metal Packaging S.A. (NYSE:AMBP) is one of the worst-performing stocks on Thursday. Ardagh Metal dropped its share prices by 16.38 percent on Thursday to close at $3.88 apiece as investors did not seem impressed by its earnings performance in the second quarter of the year. In a statement, Ardagh Metal Packaging S.A. (NYSE:AMBP) said that revenues increased by 15 percent to $1.455 billion during the period from $1.259 billion in the same quarter last year. However, net income was only $5 million, albeit higher by 150 percent than the $2 million registered in the same period last year. Looking ahead, Ardagh Metal Packaging S.A. (NYSE:AMBP) is expected to post adjusted EBITDA between $705-$725 million in the full-year period, with the figure already reflecting both improved underlying performance and favorable currency movements. Pixabay/Public Domain 'Global beverage can growth continues to benefit from innovation and share gains in our customers' packaging mix, and we still anticipate only a minimal impact to our business arising from tariff measures announced,' said Ardagh Metal Packaging S.A. (NYSE:AMBP) CEO Oliver Graham. While we acknowledge the potential of AMBP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store